Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1Classical hematology 1

Conditions

Anemia 39Neoplasms 17Neoplasms, Plasma Cell 4Waldenstrom Macroglobulinemia 3Sezary Syndrome 3Precursor T-Cell Lymphoblastic Leukemia-Lymphoma 3Precancerous Conditions 3Mycosis Fungoides 3Multiple Myeloma 3Monoclonal Gammopathy of Undetermined Significance 3Lymphoproliferative Disorders 3Lymphoma, T-Cell, Cutaneous 3Lymphoma, Non-Hodgkin 3Lymphoma, Mantle-Cell 3Lymphoma, Large-Cell, Immunoblastic 3Lymphoma, Large-Cell, Anaplastic 3Lymphoma, Large B-Cell, Diffuse 3Lymphoma, Follicular 3Lymphoma 3Lung Neoplasms 3Leukemia, Prolymphocytic 3Leukemia, Lymphocytic, Chronic, B-Cell 3Leukemia, Large Granular Lymphocytic 3Leukemia 3Immunoglobulin Light-chain Amyloidosis 3Immunoblastic Lymphadenopathy 3Hodgkin Disease 3Carcinoma, Non-Small-Cell Lung 3Prostatic Neoplasms 2Precursor Cell Lymphoblastic Leukemia-Lymphoma 2

Interventions

Darbepoetin alfa 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Pleural Effusion × Darbepoetin alfa × Classical hematology × Clear all
NCT00858364 2022-11-30

Anemia Treatment for Advanced Non-Small Cell Lung Cancer (NSCLC) Patients Receiving Chemotherapy

Amgen

Phase 3 Terminated
2,549 enrolled 19 charts
Classical hematologyThoracic

Anemia, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms, Neoplasms, Pleural Effusion, Pleural Effusion, Malignant

Data powered by HemOnc (CC BY 4.0) Colophon âš¡